Case number 1:22-cv-00227
Amgen Inc. et al v. Aurobindo Pharma Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 14, 2023 | 16 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (mdb) (Entered: 11/14/2023) (1) |
| Apr 7, 2022 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:21-cv-00662-MN. (dlw) |
| Apr 7, 2022 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: D.I. 16 has been deleted from the docket. All filings shall be made in Lead Case C.A. No. 21-662. (dlw) |
| Apr 7, 2022 | 15 | SO ORDERED (3) Docket Text: SO ORDERED re (70 in 1:21-cv-00662-MN, 14 in 1:22-cv-00227-MN) Stipulation and Order regarding consolidation. Signed by Judge Maryellen Noreika on 4/7/2022. (dlw) |
| Apr 6, 2022 | 14 | Stipulation (3) Docket Text: STIPULATION and [Proposed] Order to Consolidate by Amgen Inc., KAI Pharmaceuticals, Inc.. (Jacobs, Karen) |
| Apr 1, 2022 | 13 | Notice (Other) (3) Docket Text: NOTICE of Withdrawal of Counsel (Michelle Streifthau-Livizos) by Amgen Inc., KAI Pharmaceuticals, Inc. (Streifthau-Livizos, Michelle) |
| Mar 17, 2022 | 11 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM against All Plaintiffs by Eugia Pharma Specialties Limited, Aurobindo Pharma USA Inc., Aurobindo Pharma Limited, AuroMedics Pharma LLC.(Dorsney, Kenneth) |
| Mar 17, 2022 | 12 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Ltd. for AuroMedics Pharma LLC, Aurobindo Pharma USA Inc., Eugia Pharma Specialties Limited filed by AuroMedics Pharma LLC, Aurobindo Pharma Limited, Aurobindo Pharma USA Inc., Eugia Pharma Specialties Limited. (Dorsney, Kenneth) |
| Feb 24, 2022 | 7 | Summons Returned Executed (1) Docket Text: SUMMONS Returned Executed by Amgen Inc., KAI Pharmaceuticals, Inc.. Aurobindo Pharma Limited served on 2/24/2022, answer due 3/17/2022. (Streifthau-Livizos, Michelle) |
| Feb 24, 2022 | 8 | Summons Returned Executed (1) Docket Text: SUMMONS Returned Executed by Amgen Inc., KAI Pharmaceuticals, Inc.. Aurobindo Pharma USA Inc. served on 2/24/2022, answer due 3/17/2022. (Streifthau-Livizos, Michelle) |
| Feb 24, 2022 | 9 | Summons Returned Executed (1) Docket Text: SUMMONS Returned Executed by Amgen Inc., KAI Pharmaceuticals, Inc.. AuroMedics Pharma LLC served on 2/24/2022, answer due 3/17/2022. (Streifthau-Livizos, Michelle) |
| Feb 24, 2022 | 10 | Summons Returned Executed (1) Docket Text: SUMMONS Returned Executed by Amgen Inc., KAI Pharmaceuticals, Inc.. Eugia Pharma Specialties Limited served on 2/24/2022, answer due 3/17/2022. (Streifthau-Livizos, Michelle) |
| Feb 23, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) |
| Feb 22, 2022 | 1 | Main Document (15) Docket Text: COMPLAINT for PATENT INFRINGEMENT filed against AuroMedics Pharma LLC, Aurobindo Pharma Limited, Aurobindo Pharma USA Inc., and Eugia Pharma Specialties Limited - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3808186.) - filed by Amgen Inc. and KAI Pharmaceuticals, Inc. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(nmg) |
| Feb 22, 2022 | 1 | Exhibit A (33) |
| Feb 22, 2022 | 1 | Civil Cover Sheet (1) |
| Feb 22, 2022 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) |
| Feb 22, 2022 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/20/2022. Date of Expiration of Patent: 6/27/2034.Thirty Month Stay Deadline: 8/7/2024. (nmg) |
| Feb 22, 2022 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,162,500. (nmg) |
| Feb 22, 2022 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Amgen Inc. for KAI Pharmaceuticals, Inc. filed by Amgen Inc., KAI Pharmaceuticals, Inc. (nmg) |
| Feb 22, 2022 | 6 | Summons Issued (8) Docket Text: Summons Issued as to AuroMedics Pharma LLC, Aurobindo Pharma Limited, Aurobindo Pharma USA Inc., and Eugia Pharma Specialties Limited on 2/22/2022. (nmg) |
| Feb 22, 2022 | 1 | Complaint* (1) |
